Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.

Search Cook Medical

Peripheral Intervention


Data JEVT publishes milestone tibiopedal study
Product FDA approves new indication for Zilver® PTX®

Experience the new era in SFA treatment with drug elution

Achieve superior outcomes with the only SFA stent that has a proven drug effect.

Read More

Download the Peripheral Intervention catalog

This 2014 catalog includes more than 2,000 stock products that are approved for sale in the U.S.

Read More

Latest News

January 18th, 2017
foot_260x260

Patients suffering from critical limb ischemia (CLI) are often a difficult population to treat due to the likelihood of significant comorbidities including lesions that may be extremely difficult to cross. Increasingly, physicians are crossing these difficult lesions from a tibiopedal retrograde approach. In order to determine the technical access and crossing success rate and safety…


November 28th, 2016
thumbwheel_280

The FDA has approved a new rotating thumbwheel delivery system for Cook Medical’s Zilver® PTX® drug-eluting peripheral stent. The new system, now available for sale throughout the United States, Canada, Europe, and Japan, provides simplified deployment of the world’s first drug-eluting stent for the superficial femoral artery (SFA). Engineers in Peripheral Intervention (PI) were tasked…


September 16th, 2016
train2_306-300x192

Cook Medical recently participated in a collaborative, first-of-its-kind fellows workshop at the Interventional Radiology−Translational Research and Simulation Lab (IR−TRSL) at the Cincinnati Children’s Hospital Medical Center (CCHMC). The innovative workshop was designed for adult and pediatric IR fellows at the University of Cincinnati (UC) Medical Center and CCHMC respectively. The fellows program was the brainchild…


September 16th, 2016
Zilverptx2016-e1454608071919

Zilver PTX is now treating more patients than ever before. According to Decision Resources Group’s Peripheral Vascular Devices | US | 2016 | Market Analysis report, Zilver PTX has captured market-share leadership for revenue-based sales among all competitive stents used to treat the superficial femoral artery (SFA). DRG’s research shows that Zilver PTX went from…


July 27th, 2016
PAD_306

What is PAD? Peripheral arterial disease (PAD) is the result of narrowing of the arteries in the legs, stomach arms, and head. PAD is usually caused by atherosclerosis, a disease that causes arteries to harden due to a buildup of plaque. Symptoms of PAD include pain or cramping in the thigh, calf, or hip, especially…


June 28th, 2016
ZPTX-306x196

Check out the April 12 issue of Circulation to read about the 5-year results of the Zilver PTX randomized controlled trial in an article titled “Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.” The Cook-sponsored Zilver PTX RCT is the first and only endovascular study…


June 28th, 2016
Dr_Antonios_Gasparis_306

We recently reached out to Dr. Antonios Gasparis, professor of surgery at Stony Brook University Hospital in New York, to learn more about his hospital’s venous thromboembolism (VTE) team. Upon its formation, the team was tasked with managing patients who have received IVC filters, including tracking eligible patients for outpatient follow-up and filter retrieval. Following…


June 22nd, 2016
torcon_306

Challenging times can often be the true test of the strength of a team. In April, our teams faced one of those challenges when we decided to recall all products with Beacon Tip technology. Customers were telling us that, in some cases, the catheter tip was fracturing or separating. Decisions of this magnitude are never…


March 15th, 2016
Sitting causes DVT meme

When Joe Roberts began working with venous therapies at Cook Medical, he never imagined that he would develop a deep vein thrombosis (DVT) himself. It's given him a heightened sense of purpose in letting others know about this potentially dangerous condition.


March 13th, 2016
DVT Awareness Blog Graphics_Page_1

March is DVT Awareness Month. DVT (Deep Vein Thrombosis) can affect people of all ages and can be caused by circumstances that might not be considered as dangerous. Find out some facts that you may not know.


January 18th, 2016
EndoWar winners, from left to right: Drs. Mohammed Al-Natour, Mohammad Abbasi, Sandeep Krishnan, Adam Tanious

EndoWars is an educational opportunity for fellows and residents to practice endovascular procedures and refine their skills. A group of fellows and residents recently competed against each other to see who could complete a successful procedure in the fastest time.


January 15th, 2016

Vascular Interventional Advances (VIVA) is an annual meeting dedicated to global education in vascular medicine and intervention. VIVA 15 was an exciting meeting with late-breaking trial results and talks by leading physicians. Below are some of the topics that were discussed by physicians on the VIVA podiums: 1. Japan Post-Market Surveillance (PMS) study results provide confidence. Zilver PTX added to its strong data…


December 11th, 2015
ZPTX-306x196

Recently released data on the Japan post-market surveillance (PMS) study showed two-year patency rates of 72.3%1, while the Zilver PTX randomized controlled trial (RCT) patency results were 76.3%2 at the same mark. In addition, the Japan PMS showed 85.0%3 two-year freedom from target lesion revascularization (TLR). Two other major Zilver PTX trials showed similar numbers…


October 29th, 2015

Who has the skills it takes to win the endovascular competition at VIVA15 this year? Fellows and residents will be given the opportunity to compete against each other at the Cook booth to see who can complete an endovascular case successfully in the shortest amount of time. The winner will receive a proctorship with one of the VIVA board members.


September 28th, 2015
FreedomTower_polverini_CMYK

Dr. Danielle Cafasso and Dr. Jordan Stern, who recently completed their residencies in Hawaii and Chicago, respectively, share their thoughts on starting the first year of their vascular surgery fellowship programs at NewYork-Presbyterian/Weill Cornell Medical Center and NewYork-Presbyterian/Columbia University Medical Center. Only two fellows per year are accepted to the two-year program. Fellows spend an…


August 11th, 2015

In a recent case of chronic venous obstruction, Dr. George Erbacher chose to use the the TriForce Peripheral Crossing Set with Curved Tip Sheath and Curved Tip Catheter. Applying torque to both the inner and outer catheters as a system while keeping the tip of the angled inner catheter medial, TriForce easily crossed into the IVC.


May 19th, 2015
Dr. Sean Ryan

Dr. Sean Ryan, outgoing vascular surgery fellow, recently participated in a fellows panel discussion at SCVS. Ryan said it is helpful for incoming fellows to get peer-to-peer access because it’s hard to know what to expect.


May 12th, 2015
pedal-306x196

A tibiopedal approach showed 93.5% technical access success and 86.0% technical crossing success in a study sponsored by Cook Medical. Tibiopedal Access for Crossing of Infrainguinal Occlusions (TACO) is the world’s first multicenter, prospective, international study looking at success rates for access and crossing from a tibiopedal approach. The objective of this non-randomized, post-market, observational study was…


May 5th, 2015
Dr. Andrew Hearn

Patients who suffer from peripheral arterial disease (PAD) will often initially visit a podiatrist, who may not be aware of the disease state. To address this educational gap, Peripheral Intervention is sponsoring round tables to help podiatrists learn more about PAD.


November 4th, 2014
ZPTX_5_306

Zilver PTX drug-eluting stent study data show continued patency at five years Five-year results from the largest and longest-running clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) confirmed long-term patency for patients treated with Zilver PTX. The results were presented by Michael Dake, M.D., of Stanford University, at the 2014 Vascular…


November 3rd, 2014
lets_talk_306

Every case is different. That’s why we’ve developed the world’s broadest line of permanent and optional filters, affording you the flexibility to do what you believe is right for each of your patients. And to give you more retrieval options, we offer two retrievers: the CloverSnare® 4-Loop Vascular Retriever and the Günther Tulip® Vena Cava Filter Retrieval Set. But having…


November 3rd, 2014
lets_talk_306

To give physicians another chance at limb salvage, Cook Medical offers products that are designed to facilitate a retrograde tibiopedal approach so you can access, target, and treat. Access • The 2.9 Fr ID Micropuncture® Pedal Introducer Access Set can be used as an interventional introducer when the supplied hemostasis assembly is attached. Target • The 2.6…


October 28th, 2014
roadrunner_306

There are now four Micropucture Access Sets with trays. All of these sets include a palladium-tipped, nitinol wire guide and an EchoTip® needle. The sets, in 4 Fr and 5 Fr and standard and stiffened cannulas, also feature Transitionless-Tip™ coaxial catheter pair technology. Fewer complications In a study by Shah et al, access-site bleeding complication…


September 22nd, 2014
PAD_awareness_3_306x196

I’ve been a nurse for more decades than most of this blog’s readers have been alive. I’ve seen a lot during those years of caring for patients. When I worked in surgery, I hated amputations. Those that weren’t the result of trauma were the result of peripheral arterial disease (PAD)—and many could have been prevented….


September 18th, 2014
PAD_awareness_2_306x196

Having always been active and a sports enthusiast, Bill Doherty initially thought that the cramping in his left calf was due to muscle strain. He tried physiotherapy, but the frequency and regularity of the cramping became impossible to ignore. He also noticed that his left foot felt colder than his right foot.


September 15th, 2014
PAD_awareness_1_306x196

Bill Fischer, left, celebrates his 60th wedding anniversary with his wife, Barbara, right, their daughter, Gail McDaniel, and her partner, Keith Hamm. Bill underwent a surgical procedure to treat his advanced peripheral arterial disease. Knowing the symptoms of peripheral arterial disease (PAD) is not only important for at-risk individuals but also for their family members….


September 11th, 2014
PAD_awareness_3_306x196 (1)

Peripheral arterial disease (PAD) is a serious, underdiagnosed disease that is similar to coronary artery disease. Both develop when cholesterol levels and scar tissue build up, causing the arteries to narrow and restrict blood flow. The difference is that PAD affects arteries outside the heart. Untreated, PAD can lead to difficulty in walking and, in…


September 9th, 2014
PAD_awareness_2_306x196

The Centers for Disease Control and Prevention mapped the rapid growth of diabetes and obesity rates among Americans from 1994-2010. Diabetes and obesity are two of the main risk factors for peripheral arterial disease (PAD).   Learn more about PAD at the National Institutes of Health website. MORE ON PAD AWARENESS MONTH What is peripheral arterial…


September 9th, 2014
meetings_01_306x196

We’re looking forward to attending the annual meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Glasgow, Scotland, particularly in light of this year’s hot topic: “Interventional Radiology in the treatment of the diabetic foot.” Together with the British Society of Interventional Radiology (BSIR), CIRSE will host a press conference during which…


September 4th, 2014
PAD_awareness_1_306x196

Peripheral arterial disease (PAD) is a common circulatory problem that affects the blood vessels outside of the heart and brain. It is usually caused by atherosclerosis, systemic plaque that results in a narrowing or clogging of the vascular system. PAD usually develops over a period of years or decades, ultimately eroding the effectiveness of the…


August 5th, 2014
Dr. Nelson Bernardo 306x196

  Nelson L. Bernardo, MD, specializes in interventional cardiology and teaches a course for Vista on retrograde tibiopedal access. Dr. Bernardo is the medical director of the Peripheral Vascular Laboratory at MedStar Heart Institute. He is also the director for Peripheral Intervention at the Cardiovascular Research Institute at MedStar Research Institute. Dr. Bernardo serves as…


July 31st, 2014
stock5-widemosaic

Over time, the healthcare industry has seen incredible advancements in the level of care available to patients. It’s our belief that these innovations have happened, at least in part, as a result of physicians and healthcare providers working closely with the medical device industry. This collaboration has been a large part of our history at…


July 31st, 2014
ZPTX-306x196

As announced at the 2014 Canadian Agency for Drugs and Technologies in Health (CADTH) symposium, the Canadian Network for Environmental Scanning in Health (CNESH) has selected Cook Medical’s Zilver PTX drug-eluting peripheral stent as a top 10 game-changing health technology for 2014. The CNESH top 10 list is designed to encourage the adoption and use of effective, safe health…


July 30th, 2014
CelectPlatinum_306x196

The proven technology of the Cook Celect® Vena Cava Filter is now improved with the addition of four platinum markers. The radiopaque markers on Celect® Platinum can help physicians verify placement accuracy immediately after filter detachment. Celect Platinum features leg struts that are designed to help physicians better center the filter during placement. Also, the femoral…


July 30th, 2014
Dr. Constantio Pena 306x196

Constantino S. Peña, MD, is an interventional radiologist with Miami Vascular Specialists in Miami, Florida. Dr. Peña received his medical degree from Yale University School of Medicine. He completed an internship in internal medicine at Yale-New Haven Hospital then completed a residency in diagnostic radiology at Massachusetts General Hospital. He completed his post-graduate training with…


July 25th, 2014
ZPTX-306x196

A multicenter, international randomized trial demonstrated the clear drug effect of Zilver® PTX®.  At four years, Zilver PTX achieved a 75% patency rate, compared with 57.9% for provisional bare-metal stents.1 With Zilver PTX, you can achieve longer-lasting outcomes that are superior to the outcomes achieved by bare-metal stents. But how does the drug effect work exactly?  …


July 12th, 2014
meetings_02_306x196 (1)

Fellows with endovascular experience received valuable hands-on experience at the 2014 Mastering Cardiac and Vascular Complications conference held June 13-14 in Washington D.C. “The MCVC conference was practical and I enjoyed that it was case-based,” said Jessica Nguyen-Trong, cardiology fellow. The conference was designed to help fellows and practitioners recognize early angiographic and/or clinical telltale…


July 1st, 2014
reinterventions_bar

What do bare-metal stents do to inhibit neointimal hyperplasia? Nothing. Only Zilver PTX, with its proven drug effect,1inhibits neointimal hyperplasia. This fact not only affects patient outcomes, but also the bottom line. How can this be? Bare-metal stents and angioplasty are suboptimal. Lesions in the superficial femoral artery (SFA) are difficult to treat. One-year restenosis rates…


June 16th, 2014
NCVH_306x196

Dr. Nate Boyer, right, deploys an inferior vena cava filter in a simulator during the New Cardiovascular Horizons (NCVH) annual conference in May in New Orleans. World-renowned faculty and experts in interventional cardiology, interventional radiology, and vascular surgery instructed fellows at NCVH on how to treat patients by using some of the most innovative endovascular techniques. Cook…


June 12th, 2014
Clot_Filter_306x196

Cook Medical is engaged in two clinical studies that will provide additional data on the safety and effectiveness of inferior vena cava (IVC) filters. The first study, the Cook Inferior Vena Cava Filter (CIVC) study, will add to Cook’s existing clinical data on its commercially available IVC filters. This includes three previous studies including more than…


June 10th, 2014
ZPTX-306x196

Cook Medical launched its Zilver PTX Drug-Eluting Peripheral Stent in Canada at the Canadian Interventional Radiology Association (CIRA) meeting in Montreal, Canada. It’s the first drug-coated stent in Canada indicated to treat peripheral arterial disease (PAD) in the superficial femoral artery (SFA). “Launching Zilver PTX in Canada brings the benefits of drug-eluting stents to Canadian…


June 3rd, 2014
VCF_Track_mosaic

Because retrieval is such a vital part of the filter procedure, Cook has launched a free Vena Cava Filter Track App for iPads through the Apple® App Store™. Now you can learn how to use all of the VCF App’s support features when you visit our booth for a live demonstration during the 2014 Annual Vascular…


June 3rd, 2014
CelectPlatinum_306x196

Cook Medical is introducing the next-generation of a proven technology at the 2014 Annual Vascular Meeting of the Society for Vascular Surgery (SVS) and the SVS Foundation. Celect Platinum’s proven IVC filter is designed to enhance visibility. The specially designed anchors and platinum markers on the filter’s feet allow secure caval fixation. And, the flexibility…


May 29th, 2014
ZPTX-306x196

One-year follow-up data from 907 Japanese patients who received the Zilver PTX drug-eluting stent showed positive results in keeping open the superficial femoral artery (SFA). The postmarket surveillance (PMS) study, designed to evaluate the stent’s performance in real-world patient use, was presented at the 2014 EuroPCR meeting. The PMS study was based in Japan and presented by Hiroyoshi…


May 20th, 2014
Dr-Mark-Meissner_306x196

We sat down at the recent Venous Symposium meeting in New York City with Dr. Mark Meissner, who shared his thoughts on treating venous disease today and the trends he sees coming in the near future. Dr. Meissner is a professor of surgery at the University of Washington. He specializes in vascular surgery, with particular…


May 16th, 2014
PI_catalog_2014_306px

The new catalog for Cook Medical’s Peripheral Intervention division is now available. We offer products that enable physicians to perform entire procedures, which include the treatment of peripheral arterial disease, the prevention of recurrent pulmonary embolisms, and embolization. We also provide solutions for nonvascular stenting and specialty cardiology. This 2014 catalog includes more than 2,000 stock…


May 9th, 2014
TriForce 306x196

In the TriForce™ Peripheral Crossing Set, the enhanced crossing ability of the CXI® Support Catheter is combined with the pushability of the Flexor® Guiding Sheath to cross vascular lesions. The TriForce set features tungsten-loaded tips that aid pushability and add to radiopacity as they go through lesions. The hydrophilic coating on both the catheter and…


April 30th, 2014
35LP-306x196

The Advance 35LP Low-Profile PTA Balloon Dilatation Catheter is now available in more options in order to treat lesions of differing lengths.  The new balloon lengths are 1.5, 2, 2.5, 17, and 20 cm. The Advance 35LP balloon catheter is ideal for the superficial femoral artery and complements the Zilver® PTX® Drug-Eluting Peripheral Stent. The exceptional…


April 28th, 2014
VCF_Track_mosaic

You don’t want to forget about the vena cava filters that you place. Patient follow-up is vital, especially if retrieval is necessary. That’s why Cook Medical created a free app to help you keep track of your filter procedures. VCF Track is an organizational tool that will manage key information about filters, recipients, manufacturer brands,…


April 17th, 2014
angiosome_306

The angiosome concept of perfusion delineates specific vascular territories that are supplied by specific arteries. The concept may help vascular interventionalists treat tissue defects caused by critical limb ischemia (CLI) by enabling the interventionalists to target arteries according to the location of foot ulcers. The angiosome concept of perfusion was first described in 1987 by…


March 26th, 2014
UniGlide_306

Cook Medical’s latest addition to its broad offering of wire guides is the Roadrunner® UniGlide.® The hydrophilic UniGlide offers a familiar feel and the performance physicians expect. A durable hydrophilic coating provides trackability and pushability, and a tungsten-impregnated jacket enhances visibility. A tapered nitinol mandril offers 1:1 torque response for superb directional control. UniGlide’s more than 50…


February 10th, 2014
AdvanceMicro14_mosaic

The ultra low-profile of Cook Medical’s latest balloon allows physicians to attempt interventions that they never thought were possible. The Advance Micro™ 14 Ultra Low-Profile PTA Balloon Catheter is designed specifically to treat vessels from the knee all the way to the digital arteries. Advance Micro 14 is an .014 inch, over- the-wire system that…


February 3rd, 2014
G50002_P_003

The CXI® Support Catheter is engineered for the periphery and can help you reach and cross lesions.CXI is now available in an .014 inch platform that features platinum-iridium marker bands for exceptional visibility. CXI’s stainless steel braid provides a 1:1 torque response and exceptional pushability and kink-resistance. A hydrophilic coating on the distal 40 cm further…


January 3rd, 2014
Shuttle Tibial Infrapopliteal Access System

The Shuttle® Tibial Infrapopliteal Access System can help you target below-the-knee lesions. The system consists of a Flexor® Shuttle Guiding Sheath and a special Slip-Cath® selective catheter. Flexor Guiding Sheaths feature a hydrophilic coating, coil construction, and a soft distal tip with a radiopaque band. Slip-Cath catheters feature a hydrophilic coating, braid construction, and a radiopaque Beacon® tip. The two…


December 20th, 2013
18LP-636x320

The Advance® 18LP Low-Profile PTA Balloon Dilatation Catheter is now available in nearly 200 size, length, and shaft configuration options. Additional balloon diameters are 2, 9, and 10 mm, while additional lengths are 12, 15, 17, and 20 cm. A catheter length of 150 cm also is an option now. All sizes feature a flexible tip…


November 18th, 2013
CIRSE_3D_art_306x196

CIRSE 2013 was a celebration of both science and art. The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2013 congress drew 6,594 attendees from 94 countries to Barcelona, Spain, in September. Physicians learned about the latest advances in interventional radiology that included four-year patency results from the Zilver® PTX® randomized controlled trial. A surprise in this atmosphere of…


November 5th, 2013
AYP-Cath-lab-IR-widemosaic

Dr. Larisee Lee, a physician from Southern California, talks about her experience attending a course through Cook Medical’s Vista℠Collaboration and Learning Program. We’re confident you’ll find an equally productive experience, whether you are just getting started or simply polishing your skills. At Cook, we’ve made a commitment to working with healthcare professionals to improve patient…


October 29th, 2013
pedal-306x196

Infrapopliteal occlusions in patients with critical limb ischemia (CLI) are a challenge. The failure rate when taking the traditional, antegrade approach has been reported as high as nearly 40%.1 For such patients, amputation may be the only remaining alternative. A new revascularization technique—the retrograde approach—aims to give physicians another chance at limb salvage. In cases with…


October 7th, 2013
Zilver-306x196

This week at VIVA, Dr. Gary Ansel presented the four-year data from a randomized Zilver PTX study. The study found a 75 percent primary patency rate for patients treated with provisional Zilver PTX compared to a 57.9 patency rate for patients treated with percutaneous transluminal angioplasty with provisional bare metal stents in the study. Find…


September 9th, 2013
hands_small_PAD

CMS recently released proposed regulations for changes to their 2014 payment systems for hospital outpatient departments, ambulatory surgery centers, and physicians. There are significant changes recommended in a number of different areas. Perhaps the most significant, and most relevant to you and your customers, affect reimbursement for lower extremity interventional procedures. Remember, these are proposed…


June 20th, 2013
Thumbnail for Retracta animation

The Retracta is a detachable .035 inch coil that’s fully retractable. Physicians can use it right out of the package. It’s easy to use and requires minimal preparation time. It’s an economical choice that gives you another viable option for treating patients. The Retracta is based on the platinum Nester® technology. The soft platinum material…


June 15th, 2013
Thumbnail for retrograde access animation

[brightcove 2483297889001] Retrograde tibiopedal access is a new approach to treating the growing problem of peripheral arterial disease (PAD) and critical limb ischemia. Many physicians are discovering this technique that offers another method of crossing lesions when an attempt to cross using an antegrade approach does not work. Treatment can then be performed from either an…


January 28th, 2013
CelectPlatinum_306x196

The Venous Therapies program is dedicated to delivering next-generation devices for pulmonary embolism (PE) prevention and deep-venous disease treatment. Cook has depth, breadth, and a solid history of providing solutions for venous disease. Our broad product line offers physicians and hospitals more options. More options means greater flexibility in patient care. Our Günther Tulip® and Cook Celect® filters have one…


January 7th, 2013
AYP-Cath-lab-IR-widemosaic

The PAD Therapies program encompasses the treatment of peripheral arterial disease, particularly for patients with claudication and critical limb ischemia (CLI). Our solutions include the following products: Zilver® PTX® Drug-Eluting Peripheral Stent Zilver PTX is the first and only drug-eluting stent for the challenging anatomy of the SFA. Zilver PTX is a breakthrough technology that sets a new…


January 7th, 2013
Celect Platinum (1)

The Celect Platinum is designed to prevent recurrent pulmonary embolism (PE) via placement in the inferior vena cava. The Celect Platinum can be used as either a permanent or a retrievable device. Its secondary strut design is intended to help center the filter during placement, while its specially designed anchors allow for secure, atraumatic fixation….

Load More Posts